Table 1.
Baseline Characteristics
| Placebo (n = 16) | Roflumilast (n = 11) | |
|---|---|---|
| Age, yr | 61 ± 8 | 62 ± 7 |
| White race | 12 (75%) | 7 (64%) |
| Male sex | 10 (63%) | 7 (64%) |
| Current smoker | 10 (63%) | 6 (55%) |
| Lifetime pack-year history | 44 ± 19 | 47 ± 26 |
| GOLD stage, median (range) | 3 (2–4) | 3 (2–4) |
| Supplemental oxygen use | 4 (25%) | 3 (27%) |
| Supplemental oxygen amount, L/min | 2 ± 0 | 1.7 ± 0.6 |
| LAMA use | 8 (50%) | 6 (55%) |
| ICS or LABA/ICS use | 10 (63%) | 6 (55%) |
| Post-bronchodilator FEV1, % predicted | 44 ± 16 | 45 ± 12 |
| Post-bronchodilator FVC, % predicted | 69 ± 20 | 72 ± 17 |
| FEV1/FVC ratio | 0.48 ± 0.12 | 0.53 ± 0.12 |
| SGRQ total | 49 ± 13 | 56 ± 13 |
| BCSS | 4.6 ± 2.4 | 4.6 ± 2.7 |
| 6-min-walk distance, ft | 972 ± 255 | 739 ± 203 |
Definition of abbreviations: BCSS = Breathlessness Cough and Sputum Scale; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroid; LABA = long-acting β-agonist; LAMA = long-acting muscarinic antagonist; SGRQ = St. George’s Respiratory Questionnaire.
All results are mean ± SD or number of patients (%).
Differences between groups for each category listed were not statistically different (P > 0.05).